image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 0.1934
-5.89 %
$ 27 M
Market Cap
-0.08
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one BNGO stock under the worst case scenario is HIDDEN Compared to the current market price of 0.193 USD, Bionano Genomics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one BNGO stock under the base case scenario is HIDDEN Compared to the current market price of 0.193 USD, Bionano Genomics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one BNGO stock under the best case scenario is HIDDEN Compared to the current market price of 0.193 USD, Bionano Genomics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
36.1 M REVENUE
29.90%
-215 M OPERATING INCOME
-63.44%
-232 M NET INCOME
-75.34%
-125 M OPERATING CASH FLOW
-0.29%
24.2 M INVESTING CASH FLOW
-70.81%
114 M FINANCING CASH FLOW
394.70%
6.07 M REVENUE
-21.85%
-43.9 M OPERATING INCOME
-157.97%
-44.2 M NET INCOME
-172.72%
-13.3 M OPERATING CASH FLOW
36.56%
-5.38 M INVESTING CASH FLOW
-18.77%
6.02 M FINANCING CASH FLOW
404.40%
Balance Sheet Bionano Genomics, Inc.
image
Current Assets 140 M
Cash & Short-Term Investments 102 M
Receivables 9.66 M
Other Current Assets 28.6 M
Non-Current Assets 74.3 M
Long-Term Investments 400 K
PP&E 32.5 M
Other Non-Current Assets 41.4 M
Current Liabilities 100 M
Accounts Payable 10.4 M
Short-Term Debt 72.2 M
Other Current Liabilities 17.4 M
Non-Current Liabilities 18.2 M
Long-Term Debt 7.18 M
Other Non-Current Liabilities 11 M
EFFICIENCY
Earnings Waterfall Bionano Genomics, Inc.
image
Revenue 36.1 M
Cost Of Revenue 26.6 M
Gross Profit 9.57 M
Operating Expenses 225 M
Operating Income -215 M
Other Expenses 17.2 M
Net Income -232 M
RATIOS
26.49% GROSS MARGIN
26.49%
-595.98% OPERATING MARGIN
-595.98%
-643.74% NET MARGIN
-643.74%
-241.78% ROE
-241.78%
-108.44% ROA
-108.44%
-129.73% ROIC
-129.73%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bionano Genomics, Inc.
image
Net Income -232 M
Depreciation & Amortization 13.9 M
Capital Expenditures -1.69 M
Stock-Based Compensation 15.2 M
Change in Working Capital -14.8 M
Others 86.7 M
Free Cash Flow -127 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bionano Genomics, Inc.
image
Wall Street analysts predict an average 1-year price target for BNGO of $1.88 , with forecasts ranging from a low of $1 to a high of $3.5 .
BNGO Lowest Price Target Wall Street Target
1 USD 417.06%
BNGO Average Price Target Wall Street Target
1.88 USD 869.49%
BNGO Highest Price Target Wall Street Target
3.5 USD 1709.72%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Bionano Genomics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Jun 13, 2023
Bought 50 K USD
Mamuszka Hannah
Director
+ 65789
0.76 USD
1 year ago
May 16, 2023
Bought 9.64 K USD
Holmlin R. Erik
President and CEO
+ 15000
0.6426 USD
1 year ago
May 12, 2023
Bought 33.4 K USD
Stewart Christopher P.
Chief Financial Officer
+ 50000
0.6683 USD
2 years ago
Aug 15, 2022
Sell 72.4 K USD
Linney Yvonne
director:
- 20000
3.6201 USD
2 years ago
May 16, 2022
Bought 16 K USD
BARKER DAVID L
director:
+ 10000
1.6 USD
3 years ago
Nov 29, 2021
Bought 597 USD
Holmlin R. Erik
President and CEO
+ 150
3.98 USD
3 years ago
Nov 29, 2021
Bought 10.7 K USD
Holmlin R. Erik
President and CEO
+ 2675
3.99 USD
3 years ago
Nov 29, 2021
Bought 8.77 K USD
Holmlin R. Erik
President and CEO
+ 2200
3.985 USD
6 years ago
Aug 21, 2018
Bought 25.2 K USD
BARKER DAVID L
Director
+ 3894
6.47 USD
6 years ago
Aug 21, 2018
Bought 25.2 K USD
BARKER DAVID L
Director
+ 3894
6.47 USD
6 years ago
Aug 23, 2018
Bought 9.98 K USD
Holmlin R. Erik
President and CEO
+ 1630
6.125 USD
6 years ago
Aug 23, 2018
Bought 9.98 K USD
Holmlin R. Erik
President and CEO
+ 1630
6.125 USD
6 years ago
Aug 23, 2018
Bought 4.99 K USD
Borodkin Mark
Chief Operating Officer
+ 815
6.125 USD
6 years ago
Aug 23, 2018
Bought 4.99 K USD
Borodkin Mark
Chief Operating Officer
+ 815
6.125 USD
6 years ago
Aug 23, 2018
Bought 61.2 K USD
TWOMEY CHRISTOPHER J
Director
+ 10000
6.125 USD
6 years ago
Aug 23, 2018
Bought 61.2 K USD
TWOMEY CHRISTOPHER J
Director
+ 10000
6.125 USD
6 years ago
Aug 23, 2018
Bought 91.9 K USD
Domain Partners VIII, L.P.
10 percent owner
+ 15000
6.125 USD
6 years ago
Aug 23, 2018
Bought 91.9 K USD
Domain Partners VIII, L.P.
10 percent owner
+ 15000
6.125 USD
7. News
Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common stock equivalent) and accompanying Warrant. The Warrants have an exercise price of $0.252 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”). globenewswire.com - 1 week ago
Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common stock equivalent) and accompanying Warrant in a registered direct offering priced at-the-market under Nasdaq rules. The Warrants will have an exercise price of $0.252 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”) for a period of five years thereafter. globenewswire.com - 2 weeks ago
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway SAN DIEGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a settlement agreement and amendment to its outstanding senior secured convertible debentures due May 26, 2024 (the “Amendment”). Importantly the Amendment defers the Company's December 2024 amortization payment and reduces the payments due in January 2025 through July 2025 from $1,000,000 per month to $500,000 per month. globenewswire.com - 2 weeks ago
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Modern Pathology by a group of researchers at the Johns Hopkins University School of Medicine, showing that optical genome mapping (OGM) can outperform traditional techniques in analysis of bone and soft tissue tumors. Several prior publications have shown the utility of OGM compared to traditional cytogenetics in studies of hematologic malignancies, however, data on the application of OGM in solid tumors has been relatively sparse. This study provides compelling support for extending the utility of OGM in cancer beyond hematologic malignancies to solid tumors. globenewswire.com - 3 weeks ago
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Destiny Hance - Ladenburg Thalmann Mark Massaro - BTIG Operator Good day, and welcome to the Bionano Third Quarter 2024 Earnings Conference Call. Today's conference is being recorded. seekingalpha.com - 2 months ago
Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress Q3 2024 revenue was $6.1 million, which comprises $6.6 million in core product and software sales which is offset by $0.5 million because of a write-down of aged receivables tied to discontinued clinical service products. Q3 2024 revenue represents a 35% decrease from Q3 2023 Total installed base of 368 optical genome mapping (OGM) systems as of Q3 2024, which represents a 22% increase over Q3 2023 Sold 7,835 nanochannel array flowcells in Q3 2024, which represents a 27% increase from the number of flowcells sold in Q3 2023 Conference call today, November 13, 2024 at 4:30 PM ET SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2024. globenewswire.com - 2 months ago
Optical Genome Mapping Market to Witness 26.76% CAGR During 2024-2030 - Consumables and Reagents to Register High Growth - Bionano Genomics, Nucleome Informatics, and Praxis Genomics Dominate the Industry Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Optical Genome Mapping Market Size, Share & Trends Analysis, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global optical genome mapping market is estimated to reach USD 536.4 million by 2030. The market is projected to grow at a CAGR of 26.76% from 2024 to 2030. This can be attributed to developments in studying efficient treatments for a variety of chronic diseases. The ability of optical genome mapping (OGM) to complement other genomic sequencing technologies, such as next-generation sequencing (NGS), has created synergies in genomics research. globenewswire.com - 2 months ago
Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-marker under Nasdaq rules for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase up to an aggregate of 9,881,113 shares of common stock (collectively, the “Warrants”) at a combined offering price of $0.3039 per share of common stock and accompanying Warrants. The Warrants have an exercise price of $0.3039 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”). The Series C warrants expire five years following the date of the Stockholder Approval and the short-term Series D warrants expire eighteen months following the date of Stockholder Approval. globenewswire.com - 2 months ago
Bionano Adjourns Special Meeting of Stockholders to November 27, 2024 SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it adjourned its reconvened Special Meeting of Stockholders originally held on October 2, 2024 and subsequently adjourned to October 30, 2024 (the “Special Meeting”) because a quorum was not present at the time of the reconvened meeting. Based on preliminary reports as of October 30, 2024, approximately 30.7% of total shares outstanding as of the record date have submitted their votes, whereas 33.3% of total shares outstanding as of the record date are necessary to satisfy the quorum requirements for a meeting. globenewswire.com - 2 months ago
Bionano Announces Preliminary 3Q 2024 Revenues and Cash SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced select preliminary results for the quarter ended September 30, 2024. The Company now expects revenue for the third quarter of 2024 to be between $6.5 and $6.8 million, down from prior guidance of between $7.9 and $8.9 million. globenewswire.com - 3 months ago
Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now Bionano Genomics (BNGO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com - 4 months ago
Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript) Bionano Genomics, Inc. (NASDAQ:BNGO ) Canaccord Genuity 44th Annual Growth Results Conference August 13, 2024 3:30 PM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Kyle Mikson Hi. Welcome to the Canaccord Genuity Global Growth Conference. seekingalpha.com - 5 months ago
8. Profile Summary

Bionano Genomics, Inc. BNGO

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 27 M
Dividend Yield 0.00%
Description Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Contact 9540 Towne Centre Drive, San Diego, CA, 92121 https://www.bionanogenomics.com
IPO Date Aug. 21, 2018
Employees 344
Officers Mr. Jonathan Dixon J.D. General Counsel & Secretary Ms. Donna Polizio Global Head of Market Access Mr. Cory Kreeck Global Head of People Operations Mr. Stanislas Marin M.B.A., M.S. Vice President of Global Sales Dr. Robert Erik Holmlin M.B.A., Ph.D. President, Chief Executive Officer & Director and Chief Financial Officer Mr. Mark Adamchak CPA Vice President of Accounting & Controller Mr. Mark Oldakowski Chief Operating Officer Dr. Alka Chaubey FACMG, Ph.D. Chief Medical Officer